open access

Vol 25, No 1 (2018)
Letters to the Editor — Interventional cardiology
Published online: 2018-02-27
Get Citation

Impact of post-dilatation on strut apposition of second-generation bioresorbable vascular scaffolds: Key role for scaffold thrombosis and prognosis?

Antonio H. Frangieh, Milosz Jaguszewski, Yoichi Imori, Slayman Obeid, Christian Templin
DOI: 10.5603/CJ.2018.0013
·
Pubmed: 29512102
·
Cardiol J 2018;25(1):148-150.

open access

Vol 25, No 1 (2018)
Letters to the Editor — Interventional cardiology
Published online: 2018-02-27

Abstract

Not available

Abstract

Not available
Get Citation
About this article
Title

Impact of post-dilatation on strut apposition of second-generation bioresorbable vascular scaffolds: Key role for scaffold thrombosis and prognosis?

Journal

Cardiology Journal

Issue

Vol 25, No 1 (2018)

Pages

148-150

Published online

2018-02-27

DOI

10.5603/CJ.2018.0013

Pubmed

29512102

Bibliographic record

Cardiol J 2018;25(1):148-150.

Authors

Antonio H. Frangieh
Milosz Jaguszewski
Yoichi Imori
Slayman Obeid
Christian Templin

References (14)
  1. Gomez-Lara J, Radu M, Brugaletta S, et al. Serial analysis of the malapposed and uncovered struts of the new generation of everolimus-eluting bioresorbable scaffold with optical coherence tomography. JACC Cardiovasc Interv. 2011; 4(9): 992–1001.
  2. Mattesini A, Secco GG, Dall'Ara G, et al. ABSORB biodegradable stents versus second-generation metal stents: a comparison study of 100 complex lesions treated under OCT guidance. JACC Cardiovasc Interv. 2014; 7(7): 741–750.
  3. Jaguszewski M, Ghadri JR, Zipponi M, et al. Feasibility of second-generation bioresorbable vascular scaffold implantation in complex anatomical and clinical scenarios. Clin Res Cardiol. 2015; 104(2): 124–135.
  4. Capodanno D, Gori T, Nef H, et al. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention. 2015; 10(10): 1144–1153.
  5. Lee R, Foin N, Ng J, et al. Early coverage of drug-eluting stents analysed by optical coherence tomography: evidence of the impact of stent apposition and strut characteristics on the neointimal healing process. EuroIntervention. 2016; 12(5): e605–e614.
  6. Imori Y, D'Ascenzo F, Gori T, et al. Impact of postdilatation on performance of bioresorbable vascular scaffolds in patients with acute coronary syndrome compared with everolimus-eluting stents: A propensity score-matched analysis from a multicenter "real-world" registry. Cardiol J. 2016; 23(4): 374–383.
  7. Karanasos A, Van Mieghem N, van Ditzhuijzen N, et al. Angiographic and optical coherence tomography insights into bioresorbable scaffold thrombosis: single-center experience. Circ Cardiovasc Interv. 2015; 8(5).
  8. Sotomi Y, Suwannasom P, Serruys PW, et al. Possible mechanical causes of scaffold thrombosis: insights from case reports with intracoronary imaging. EuroIntervention. 2017; 12(14): 1747–1756.
  9. Naganuma T, Latib A, Panoulas VF, et al. Why do we need post-dilation after implantation of a bioresorbable vascular scaffold even for a soft lesion? JACC Cardiovasc Interv. 2014; 7(9): 1070–1072.
  10. Abellas-Sequeiros RA, Ocaranza-Sanchez R, Galvão Braga C, et al. "Assessment of effectiveness and security in high pressure postdilatation of bioresorbable vascular scaffolds during percutaneous coronary intervention. Study in a contemporary, non-selected cohort of Spanish patients". Int J Cardiol. 2016; 219: 264–270.
  11. Onuma Y, Serruys PW, Ormiston JA, et al. Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial. EuroIntervention. 2010; 6(4): 447–453.
  12. Gori T, Schulz E, Hink U, et al. Early outcome after implantation of Absorb bioresorbable drug-eluting scaffolds in patients with acute coronary syndromes. EuroIntervention. 2014; 9(9): 1036–1041.
  13. Serruys PW, Chevalier B, Sotomi Y, et al. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial. Lancet. 2016; 388(10059): 2479–2491.
  14. Kajiya T, Liang M, Sharma RK, et al. Everolimus-eluting bioresorbable vascular scaffold (BVS) implantation in patients with ST-segment elevation myocardial infarction (STEMI). EuroIntervention. 2013; 9(4): 501–504.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl